2022 World Conference on Lung Cancer (ePosters)-EP05.01-024. Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study

EP05.01-024. Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study

Pdf Summary

The 'Italian oBsErvational study on Patient mAnagement strategies in real-world Clinical practIce For patIents with loCally advanced (stage III) NSCLC' (BE-PACIFIC) aimed to describe diagnostic work-up and treatment strategies of stage III Non-Small Cell Lung Cancer (NSCLC) patients in Italy and to evaluate survival outcomes. The study involved 311 patients, with 296 considered eligible and included for analysis. <br /><br />The median duration of the diagnostic process was 30.4 days, with 48.6% of patients completing the work-up in a single cancer center. A multidisciplinary team (MDT) was involved in 88.7% of patients' treatment plan definition. Among the diagnostic procedures, radiological/imaging examinations for clinical staging and cyto/histopathologic analyses for pathological confirmation were the most performed. PD-L1 level testing was initially done in 196 patients, with 67.9% showing 1% of tumor cells expressing PD-L1. Additional PD-L1 testing was performed in 59 patients during observation. <br /><br />The study found that 48% of non-resected patients treated with chemoradiation received the programmed death-ligand 1 (PD-L1) inhibitor durvalumab as consolidation immunotherapy. Durvalumab treatment was well-tolerated, and response was observed in 23.9% of patients evaluated for best response. Disease progression or death occurred in 51.7% of patients during the observation period.<br /><br />Overall, the study highlights the importance of a multidisciplinary approach in the management of stage III NSCLC patients and the use of durvalumab as consolidation immunotherapy following chemoradiation. The findings provide insights into real-world practice and outcomes in stage III NSCLC in Italy.

Asset Subtitle

Paolo Bironzo

Meta Tag

Speaker Paolo Bironzo

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

Italian oBsErvational study

stage III NSCLC

diagnostic work-up

treatment strategies

PD-L1 level testing

durvalumab

consolidation immunotherapy

chemoradiation

response

multidisciplinary approach